SOMERSET, NJ – June 9, 2020 – Legend Biotech (NASDAQ: LEGN) announced today that it has appointed Dr. Corazon (Corsee) Dating Sanders, Dr. Darren Ji, and Mr. Philip Yau to the company’s Board of Directors. Dr. Sanders joined the Legend Biotech Board of Directors in May 2020. She has over 25 years of experience in […]
SOMERSET, NJ – June 9, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the closing of its initial public offering of 21,188,750 American depositary shares (ADSs), each representing two ordinary shares, at […]
SOMERSET, NJ – June 5, 2020 – Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the pricing of its initial public offering of 18,425,000 American depositary shares (ADSs), each representing two ordinary shares, at […]
Longer-term follow up data (median of 11.5 months) from the Phase 1b portion of the CARTITUDE-1 study demonstrated 100% overall response rate, 86% stringent complete response rate and a 9 month progression free survival rate of 86%. Somerset, N.J., May 13, 2020 – Legend Biotech Corporation (“Legend”) announced today updated results from the Janssen Pharmaceutical […]
Collaboration focuses on advancing the next generation of T-cell products for the treatment of solid tumors Somerset, NJ, USA and Tokyo, Japan; May 4, 2020 – Legend Biotech Corporation (“Legend”), a global clinical stage biopharmaceutical company engaged in the discovery and development of novel cell therapies, announced today that Legend and Noile-Immune Biotech, Inc. (“NoileImmune”), […]
Thank you for your interest in learning more about Legend Biotech.
media@legendbiotech.com